{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:24:29Z","timestamp":1791267869777,"version":"4.1.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1097\/inf.0b013e318235c7aa","type":"journal-article","created":{"date-parts":[[2011,10,6]],"date-time":"2011-10-06T04:53:53Z","timestamp":1317876833000},"page":"164-170","source":"Crossref","is-referenced-by-count":66,"title":["Prevalence of Congenital Anomalies in Infants With In Utero Exposure to Antiretrovirals"],"prefix":"10.1097","volume":"31","author":[{"given":"Katherine M.","family":"Knapp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan B.","family":"Brogly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Muenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans M. L.","family":"Spiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Conway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendolyn B.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey T.","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"RR-11","key":"R1-15-20210202","first-page":"1","article-title":"Recommendations of the U.S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus.","volume":"43","year":"1994","journal-title":"MMWR Recomm Rep"},{"key":"R2-15-20210202","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1056\/NEJM199411033311801","article-title":". Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.","volume":"331","author":"Connor","year":"1994","journal-title":"N Engl J Med"},{"key":"R3-15-20210202","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJM199611283352201","article-title":". Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.","volume":"335","author":"Sperling","year":"1996","journal-title":"N Engl J Med"},{"key":"R4-15-20210202","first-page":"812","article-title":"Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective Nat Rev Drug D","volume":"2","author":"Lewis","year":"2003","journal-title":"iscov"},{"key":"R5-15-20210202","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1517\/14740338.5.3.373","article-title":"Mitochondrial disease in the offspring as a result of antiretroviral therapy.","volume":"5","author":"Venhoff","year":"2006","journal-title":"Expert Opin Drug Saf"},{"key":"R6-15-20210202","doi-asserted-by":"crossref","first-page":"e1189","DOI":"10.1542\/peds.2008-2771","article-title":". Antiretroviral exposure and lymphocyte mtDNA content among uninfected infants of HIV-1-infected women.","volume":"124","author":"Aldrovandi","year":"2009","journal-title":"Pediatrics"},{"key":"R7-15-20210202","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/toxsci\/kfq235","article-title":". Progressive mitochondrial compromise in brains and livers of primates exposed in utero to nucleoside reverse transcriptase inhibitors (NRTIs).","volume":"118","author":"Divi","year":"2010","journal-title":"Toxicol Sci"},{"key":"R8-15-20210202","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1089\/aid.2010.0204","article-title":". Transplacental nucleoside analogue exposure and mitochondrial parameters in HIV-uninfected children.","volume":"27","author":"Brogly","year":"2011","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R9-15-20210202","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1001\/jama.285.16.2083","article-title":". Agence Nationale de Recherches sur le SIDA (ANRS) 075 Study Group. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1.","volume":"285","author":"Mandelbrot","year":"2001","journal-title":"JAMA"},{"key":"R10-15-20210202","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/00042560-200204150-00009","article-title":". Women and Infants Transmission Study Group. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission.","volume":"29","author":"Cooper","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R11-15-20210202","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jama.288.2.189","article-title":". International PACTG 316 Team. Two-dose intrapartumnewborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial.","volume":"288","author":"Dorenbaum","year":"2002","journal-title":"JAMA"},{"key":"R14-15-20210202","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1097\/QAD.0b013e32833a2a14","article-title":". Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts.","volume":"24","author":"Ford","year":"2010","journal-title":"AIDS"},{"key":"R15-15-20210202","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/sj.jp.7211343","article-title":". Myelomeningocele in an infant with intrauterine exposure to efavirenz.","volume":"25","author":"Saitoh","year":"2005","journal-title":"J Perinatol"},{"key":"R16-15-20210202","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00002030-200201250-00025","article-title":". Myelomeningocele in a child with intrauterine exposure to efavirenz.","volume":"16","author":"Fundaro","year":"2002","journal-title":"AIDS"},{"key":"R17-15-20210202","first-page":"1","article-title":"Update on overall prevalence of major birth defectsAtlanta, Georgia, 1978-2005.","volume":"57","year":"2008","journal-title":"Morb Mortal Wkly Rep"},{"key":"R18-15-20210202","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/aje\/153.10.961","article-title":". Neural tube defects in relation to use of folic acid antagonists during pregnancy.","volume":"153","author":"Hernandez-Diaz","year":"2001","journal-title":"Am J Epidemiol"},{"key":"R19-15-20210202","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1212\/01.wnl.0000227919.81208.b2","article-title":". In utero antiepileptic drug exposure: fetal death and malformations.","volume":"67","author":"Meador","year":"2006","journal-title":"Neurology"},{"key":"R20-15-20210202","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0301-2115(00)00288-8","article-title":". Spinal malformations in the fetuses of HIV infected women receiving combination antiretroviral therapy and co-trimoxazole.","volume":"93","author":"Richardson","year":"2000","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R21-15-20210202","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1136\/sti.77.6.441","article-title":". Is first trimester exposure to the combination of antiretroviral therapy and folate antagonists a risk factor for congenital abnormalities.","volume":"77","author":"Jungmann","year":"2001","journal-title":"Sex Transm Infect"},{"key":"R22-15-20210202","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1056\/NEJMoa067407","article-title":". First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects.","volume":"356","author":"Louik","year":"2007","journal-title":"N Engl J Med"},{"key":"R23-15-20210202","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/bdra.20641","article-title":". First-trimester use of paroxetine and congenital heart defects: a population-based case-control study.","volume":"88","author":"Bakker","year":"2010","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"R24-15-20210202","first-page":"7","article-title":"Risk of selected birth defects with prenatal illicit drug use, Hawaii, 1986-2002 J Toxicol Environ Health","volume":"70","author":"Forrester","year":"2007","journal-title":"A"},{"key":"R25-15-20210202","first-page":"e132","article-title":"Profile of the first 1,400 patients receiving diagnostic evaluations for fetal alcohol spectrum disorder at the Washington State Fetal Alcohol Syndrome Diagnostic Prevention Network.","volume":"17","author":"Astley","year":"2010","journal-title":"Can J Clin Pharmacol"},{"key":"R28-15-20210202","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/INF.0b013e3181e74a2f","article-title":". Birth defects among children born to human immunodeficiency virus-infected women: Pediatric AIDS Clinical Trials Protocols 219 and 219C.","volume":"29","author":"Brogly","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R29-15-20210202","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/bdra.20294","article-title":". National estimates and raceethnic-specific variation of selected birth defects in the United States, 1999-2001.","volume":"76","author":"Canfield","year":"2006","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"R30-15-20210202","first-page":"116","article-title":". European Collaborative Study.","volume":"40","author":"Patel","year":"2005","journal-title":"Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-infected women J Acquir Immune Defic Syndr"},{"key":"R31-15-20210202","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/QAD.0b013e328326ca8e","article-title":". Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007.","volume":"23","author":"Townsend","year":"2009","journal-title":"AIDS"},{"key":"R32-15-20210202","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/QAI.0b013e31802e2229","article-title":". Assessment of birth defects according to maternal therapy among infants in the Women and Infants Transmission Study.","volume":"44","author":"Watts","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R33-15-20210202","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/QAI.0b013e3181c5c81f","article-title":". Maternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI Perinatal Study.","volume":"53","author":"Joao","year":"2010","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006454-201202000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:22:59Z","timestamp":1786047779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006454-201202000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e318235c7aa","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}